News | Radiation Therapy | September 27, 2016

Post-operative Stereotactic Radiosurgery New Standard for Patients with Resected Brain Metastases

Multi-institutional trial finds comparable survival, less cognitive decline and better quality of life following SRS versus whole brain radiotherapy after resection

stereotactic radiosurgery, SRS, standard of care, resected brain metastases, ASTRO 2016

September 27, 2016 — For patients who have cancer that has metastasized to the brain, stereotactic radiosurgery (SRS) results in statistically comparable survival rates, reduced cognitive decline and better quality of life (QOL), compared to whole brain radiotherapy (WBRT). These findings were drawn from research presented at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO), Sept. 25-28 in Boston.

Surgical resection of large symptomatic brain metastases is often indicated to confirm diagnosis, remove the lesion(s) or reduce pressure within the brain, but there is a high incidence of tumor recurrence after surgery alone. Although post-operative WBRT significantly reduces tumor recurrence in the brain and is the current standard of care for patients following resection, the treatment can negatively impact a patient’s cognitive function and quality of life. SRS targets escalated doses of radiation to the tumor with extreme precision; the advanced technique can eliminate cancerous cells in a single or very small number of sessions while limiting the impact on surrounding tissue.

“Stereotactic radiosurgery to the surgical cavity is widely used, despite the lack of clinical trials to substantiate its effectiveness,” said Paul D. Brown, M.D., lead author of the study and a radiation oncologist at the Mayo Clinic in Rochester, Minn. “Our multi-institutional, randomized trial is the first to demonstrate clearly the efficacy of SRS compared to WBRT in a post-operative setting.”

The trial was conducted at cancer centers across the United States and Canada from 2011 to 2015. Participants included 194 patients, each with one to four brain metastases. Patients were randomized to receive either SRS or WBRT after surgical resection of one lesion. The majority of patients (77 percent) had a single brain metastasis, and lung tumors were the primary site for most patients (59 percent). The average patient age was 61 years, and study arms were balanced on baseline patient and tumor characteristics.

Primary outcomes in the trial included overall survival (OS) and cognitive deterioration-free survival (CDFS), which was defined as a decline greater than one standard deviation from the patient’s baseline in any of six cognitive tests. Major secondary endpoints included local control of the surgical bed, time to intracranial failure and quality of life (QOL). Researchers computed Hazard Ratios (HR) to compare outcomes between treatment arms.

With a median follow-up of 15.6 months, there was no statistically significant difference in overall survival rates between treatment groups, with a median OS of 11.5 months following SRS and 11.8 months following WBRT (p = 0.65). Moreover, SRS patients experienced significantly longer survival without cognitive decline, with a median CDFS of 3.2 months for SRS and 2.8 months for WBRT (HR, 2.0; p < 0.0001).

The cognitive impact of WBRT persisted at six months following treatment. The rate of cognitive deterioration at six months was 85.7 percent after WBRT, compared to 53.8 percent after SRS (p = 0.0006), with a higher percentage of WBRT patients experiencing worse immediate recall, memory and attention compared to those treated with SRS.

WBRT did provide higher overall intracranial tumor control; rates at six and 12 months were 90 and 78.6 percent with WBRT versus 74 and 54.7 percent with SRS (p < 0.0001). There was no clinically meaningful difference in median surgical bed relapse-free survival between treatment arms, although long-term follow-up showed better control with WBRT (7.7 months vs. 7.5 months, p = 0.04).

Patients treated with SRS experienced better quality of life than those who received WBRT. At three months following treatment, declines in QOL and physical wellbeing were significantly smaller after SRS than WBRT (mean QOL change from baseline: -1.5 vs. -7.0, p = 0.03; mean wellbeing change from baseline: - 6.4 vs. -20.2, p = 0.002). At six months, physical wellbeing (decline of -3.2 vs. -15.1, p = 0.016) remained significantly better for SRS patients for.

“Our results confirm that radiosurgery to the surgical cavity is a viable treatment option to improve local control with less impact on cognitive function and quality of life compared to WBRT,” said Brown. “There is no significant difference in survival whether a patient receives post-operative radiosurgery or WBRT, and radiosurgery avoids the well-known toxicities of WBRT. Furthermore, due to less time commitment and a quicker recovery after SRS, patients can restart systemic therapies more rapidly. Radiosurgery to the surgical cavity after resection of brain metastases should be considered a standard of care and a less toxic alternative than the historic standard of care WBRT.”

For more information:

Related Content

Life Image and Bringing Artificial Intelligence to Clinical Trial Development
News | Artificial Intelligence | November 15, 2018
Life Image and announced a new strategic partnership that will facilitate the adoption and enhancement of...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Merit Medical Completes Acquisition of Cianna Medical
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the 
The Fujifilm FCT Embrace CT System displayed for the first time at ASTRO 2018.
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for radiation therapy displayed for the first time since gaining FDA clearance in 2018. It was displayed at the American Society for Radiotherapy and Oncology (ASTRO) 2018 annual meeting. Read more about this system at ASTRO 2018. #ASTRO18 #ASTRO2018
360 Photos | 360 View Photos | November 07, 2018
This is the Siemens Magnetom Sola RT edition 1.5T MRI system optimized for...